This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Veltuzumab

Immunomedics, Inc.

Drug Names(s): IMMU-106, CD20 antibody, hA20

Description: IMMU-106 is a humanized antibody targeting the CD20 antigen, which is present on the surface of mature B cells. From there, they may recruit the body's natural defenses to attack and kill the targeted B-cells. Stem cells (B-cell progenitors) in bone marrow lack the CD20 antigen, allowing healthy B-cells to regenerate after treatment and return to normal levels within several months.

Deal Structure: Nycomed and Immunomedics
In July 2008, Nycomed and Immunomedics announced a collaboration and licensing agreement on Immunomedics' veltuzumab. Under the agreement, Nycomed will receive the exclusive, worldwide rights to develop, manufacture and commercialise the subcutaneous formulation of veltuzumab for the treatment of all non-cancer indications. Nycomed will purchase clinical trial materials from Immunomedics at cost-plus and will source a third party CMO for commercial scale manufacturing of veltuzumab. The agreement provides Immunomedics with an option to co-promote veltuzumab for the ITP indication in the United States and a non-refundable initial cashpayment of $40 million with potential milestone payments of up to $580 million in cash, as well as escalating double-digit royalties on sales of veltuzumab.

Nycomed and Takeda
In May 2011, Takeda Pharmaceutical and Nycomed jointly announced that Takeda has reached an agreement with the shareholders of...See full deal structure in Biomedtracker


Veltuzumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug